Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography

Basit Öğe Kaydı
dc.authoridOner, Serkan/0000-0002-7802-880X
dc.authoridTuran, Muhammed Kamil/0000-0002-1086-9514
dc.authoridYildiz Gulhan, Pinar/0000-0002-5347-2365
dc.authoridAcat, Murat/0000-0002-7163-4882
dc.authorwosidOner, Serkan/T-2518-2019
dc.authorwosidTuran, Muhammed Kamil/Q-1010-2017
dc.authorwosidAcat, Murat/A-8867-2019
dc.contributor.authorAcat, Murat
dc.contributor.authorGulhan, Pinar Yildiz
dc.contributor.authorOner, Serkan
dc.contributor.authorTuran, Muhammed Kamil
dc.date.accessioned2021-12-01T18:49:48Z
dc.date.available2021-12-01T18:49:48Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractAim We aimed to investigate the effect of short-term pirfenidone treatment on prolonged COVID-19 pneumonia. Method Hospital files of patients hospitalised with a diagnosis of critical COVID-19 pneumonia from November 2020 to March 2021 were retrospectively reviewed. Chest computed tomography images taken both before treatment and 2 months after treatment, demographic characteristics and laboratory parameters of patients receiving pirfenidone + methylprednisolone (n = 13) and only methylprednisolones (n = 9) were recorded. Pulmonary function tests were performed after the second month of the treatment. CT involvement rates were determined by machine learning. Results A total of 22 patients, 13 of whom (59.1%) were using methylprednisolone + pirfenidone and 9 of whom (40.9%) were using only methylprednisolone were included. When the blood gas parameters and pulmonary function tests of the patients were compared at the end of the second month, it was found that the FEV1, FEV1%, FVC and FVC% values were statistically significantly higher in the methylprednisolone + pirfenidone group compared with the methylprednisolone group (P = .025, P = .012, P = .026 and P = .017, respectively). When the rates of change in CT scans at diagnosis and second month of treatment were examined, it was found that the involvement rates in the methylprednisolone + pirfenidone group were statistically significantly decreased (P < .001). Conclusion Antifibrotic agents can reduce fibrosis that may develop in the future. These can also help dose reduction and/or non-use strategy for methylprednisolone therapy, which has many side effects. Further large series and randomised controlled studies are needed on this subject.en_US
dc.identifier.doi10.1111/ijcp.14961
dc.identifier.issn1368-5031
dc.identifier.issn1742-1241
dc.identifier.pmid34624155en_US
dc.identifier.scopus2-s2.0-85117142372en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1111/ijcp.14961
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10780
dc.identifier.wosWOS:000707795400001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal Of Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPulmonary-Fibrosisen_US
dc.titleComparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomographyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10780.pdf
Boyut:
3.6 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu